Dr. David Kung Recruits Patients for Clinical Study of HydraSolve® vs. Traditional Liposuction in Flanks Treatment.

TUSTIN, Calif., Feb. 3, 2016 /PRNewswire/ -- Andrew Technologies LLC announces that Dr. David Kung of Kung Plastic Surgery is now recruiting patients for a multicenter, controlled clinical trial of HydraSolve^® vs. suction assisted liposuction (the most common form of traditional liposuction). If qualified for the study, patients will receive extraction of excess fat in their flanks (low back) and will be compensated for their time as they report on their progress in recovery.

The purpose of this research is to compare the use of two different methods of liposuction, HydraSolve^® and suction-assisted liposuction.  All devices used in this study are FDA cleared.  This study is being done to determine if one method of liposuction is better than the other, or if they are the same. HydraSolve^® employs Tissue Liquefaction Technology as a safe non-cutting energy source which transitions fat tissue from a solid to a liquid; without affecting blood vessels, nerves and connective tissues so fat tissue can be aspirated from the body through a tiny incision.

Suction assisted liposuction is different from HydraSolve^® because the mechanism of action which, allows removal of fat tissue, is the cutting of fat tissue (and non-targeted tissues) into small pieces to allow the fat to be removed. Both methods of liposuction used in this study, HydraSolve^® and suction-assisted, are FDA cleared. Patients who agree to take part in this study, will need to be seen a total of four (4) visits with each visit lasting approximately 30 to 45 minutes.  

Study subjects may experience one or more of the known liposuction risks indicated below from being in this study. These risks are: infection, bleeding, seroma formation, contour irregularity, numbness or tingling, prolonged swelling, skin necrosis, fluid imbalance, unintended perforation of an internal organ, and embolism which in some instances can be fatal.

About HydraSolve^®
HydraSolve^® is a body contouring device based on the same patented Tissue Liquefaction Technology™ that was launched in 2003 by Alcon as the AquaLase^® Liquefaction Device for precision cataract surgery. HydraSolve^® combines natural saline solution with low levels of temperature and pressure, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve^® cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue.  It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while not liquefying or cutting blood vessels, nerves or connective tissue. HydraSolve^® achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes. HydraSolve^® is the first liposuction device FDA cleared for autologous fat transfer. For more information, please refer to www.hydrasolve.com  HydraSolve^® is designed to contour the body by removing localized deposits of excess fat and is not intended to treat obesity. Liposuction is a surgical procedure that has risks similar to other minimally invasive cosmetic surgeries.

About Andrew Technologies, LLC
Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients' lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. In addition to HydraSolve^®, Andrew Technologies has an impressive research pipeline to include minimally invasive surgery to correct type 2 diabetes and adipose stem cell isolation. Andrew Technologies is a privately funded company.

Logo - http://photos.prnewswire.com/prnh/20140923/147927 

SOURCE Andrew Technologies